



November 07, 2025

Ref:- GHL/2025-26/EXCH/76

The General Manager
Dept. of Corporate Services
BSE Limited,
P J Towers, Dalal Street,
Mumbai - 400 001

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

Scrip Code: 543654

Symbol: MEDANTA

Sub: Press Release

Dear Sir(s),

Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release, for the Second Quarter and Half Year ended September 30, 2025 Results.

Kindly take the above on record.


Thanking you,

Yours faithfully

For Global Health Limited

Rahul Ranjan
Company Secretary & Compliance Officer
M. No. A17035

Encl: a/a



Medanta expands its footprint with a new 550-bed super speciality hospital in Noida, strengthening its leadership in Delhi/NCR

Consolidated Total Income of INR 11,189 million in Q2 FY26; up by 14.8% y-o-y and 6.4% q-o-q

EBITDA ex Noida of INR 2,804 million, up by 13.7% y-o-y and 9.8% q-o-q

Net Profit of INR 1,584 million, up by 21.1% y-o-y

Gurugram, 7th November, 2025: Global Health Limited (NSE: [Medanta](#), BSE: [543654](#)), one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India, today announced its audited consolidated financial results for the quarter ending 30th September, 2025.

Consolidated Highlights of the Quarter Ended 30th September, 2025 (Q2 FY2026)

- Consolidated Total Income of INR 11,189 million, compared to INR 9,748 million in Q2 FY25; reflecting a growth of 14.8 % y-o-y
- EBITDA¹ (ex-Noida³) grew 13.7 % y-o-y to INR 2,804 with margins of 25.2% compared to 25.3% in Q2 FY25. Including Noida, EBITDA was INR 2,607 million, up 5.7% y-o-y, with margins at 23.3%
- Medanta Noida commenced operations in September 2025. The hospital generated Revenue of INR 39 million and EBITDA loss of INR 197 million
- Profit After Tax was INR 1,584 million, growth of 21.1% y-o-y. PAT margins improved to 14.2% from 13.4% in Q2 FY25
- During the quarter, 37 new beds were added at Patna, taking total bed addition to 57 beds in H1 FY26 in Patna
- Occupied bed days increased by 7.7% y-o-y, representing an occupancy of ~64% on increased bed capacity
- ARPOB grew by 5.5% y-o-y to INR 65,570 in Q2 FY26, driven by increase in realization and change in speciality mix
- Volume growth remained robust, In-patient count increased by 12.7% and Out-patient count increased by 14.9% y-o-y
- Matured hospitals revenue was INR 7,200 million, growth of 5.4% y-o-y. EBITDA was INR 1,696 million, growth of 0.4% y-o-y
- Developing hospitals ex Noida, Revenue was INR 3,531 million, growth of 28.3% y-o-y. EBITDA increased 34.0% YoY to INR 1,112 million, with margins improving to 31.5% compared to 30.1% in Q2 FY25. Including Noida, EBITDA stood at INR 915 million, with margin of 25.6%, reflecting the impact of initial ramp-up costs
- International Patients Revenue increased by 48.5% y-o-y to INR 762 million in Q2 FY26, driven by increased international patient volume
- OPD Pharmacy (Hospital & Retail) continues to register strong double digit growth. Revenue increased by 23.9% y-o-y to INR 456 million in Q2 FY26

Commenting on Q2 FY2026 results, Mr. Pankaj Sahni, Group CEO and Director said:

“We are extremely pleased to share that in September 2025, we launched our sixth hospital, a state-of-the-art, 550-bed facility in Noida. Over 150 doctors across key specialties have already joined the hospital, supported by the deployment of advanced medical technologies, they will be able to deliver world-class care in the region. We are encouraged by the initial response from the community and are progressively ramping up operations.

During the quarter, the Company delivered a strong performance, with Revenue Growth of 15% year-on-year and 6% sequential growth. EBITDA (excluding Noida) grew 14% year-on-year and 10% sequentially. Growth momentum remained broad-based across our network.

Key Developments – Q2 FY2026

- Medanta strengthens its presence in Delhi/NCR with the commencement of its world-class 550-bed hospital in Noida. The facility is currently operational with 226 beds, 81 ICU beds, 5 operating theatres, and is fully equipped with advanced medical technology
- At Medanta Patna, 37 new beds were added during the quarter, taking the total addition to 57 beds in H1 FY26 in Patna
- During the quarter, over 200 doctors were on-boarded across the Medanta network, including 151 doctors in Noida and 49 across other network hospitals, further strengthening the Group's clinical capabilities
- A new MAGNETOM Vida 3T MRI scanner with BioMatrix technology was commissioned at Medanta Patna, enhancing precision imaging capabilities
- At Medanta Lucknow, a 128-slice Dual Source CT and a MAGNETOM Altea 1.5T MRI were added, expanding the hospital's advanced imaging and diagnostic infrastructure
- Initiated a year-long Cancer Awareness Program to drive early detection and prevention efforts across various cancers. The inaugural campaign, focused on breast cancer and the “BannokiRasam”, became widely recognized for its viral awareness video that broke social taboos and encouraged women to undergo early screening through community-driven engagement and education.
- **Guwahati Project Update:** In October, Medanta acquired a 3.5-acre land parcel in Guwahati for ~INR 600 million. Allotment and possession were completed, and the Bhoomi Poojan was held on 31st October 2025
- **Mumbai Project Update:** Medanta has announced plan to build 500+ bed super-specialty hospital in Oshiwara. Additional FSI approval received and the increased FSI has raised the allowable built-up area enabling an increase in bed capacity from 500 to 750. The Board of Directors, have approved the project cost including land and FSI purchase is estimated at ~INR 15,300 million. The project cost includes land cost, additional FSI purchase as well as an investment of up to INR 850 million for residential apartments for Medanta staff

Financial Highlights: Q2 and H1 FY26

INR million	Half Year			Quarter			
	H1 FY2025	H1 FY2026	Y-o-Y Growth %	Q2 FY25	Q1 FY26	Q2 FY26	Y-o-Y Growth %
Revenue from operations	18,176	21,301	17.2%	9,566	10,308	10,992	14.9%
Other income	401	402	0.1%	182	205	197	8.3%
Total income	18,578	21,702	16.8%	9,748	10,513	11,189	14.8%
Cost of materials consumed	4,368	4,946	13.2%	2,280	2,391	2,556	12.1%
Employee benefits expense	6,563	8,045	22.6%	3,366	3,852	4,193	24.6%
Other expenses	3,099	3,551	14.6%	1,637	1,717	1,834	12.1%
EBITDA	4,548	5,160	13.5%	2,465	2,553	2,607	5.7%
EBITDA Margins %	24.5%	23.8%	(70) bps	25.3%	24.3%	23.3%	(199) bps
ESOP Expenses	0	179	na	0	79	100	na
EBITDA after ESOP Expenses	4,548	4,981	9.5%	2,465	2,474	2,507	1.7%
Finance costs	340	309	(9.0)%	160	138	171	7.1%
Depreciation and amortization expense	960	948	(1.3)%	494	451	497	0.6%
Exceptional item	0	(356)	na	0	(196)	(160)	na
Profit before tax	3,248	4,080	25.6%	1,811	2,081	1,998	10.3%
Tax expenses	877	906	3.3%	503	492	414	(17.7)%
Profit after tax	2,371	3,174	33.9%	1,308	1,590	1,584	21.1%

Note:

1. EBITDA represents EBITDA before ESOP expenses
2. Noida generated Total Income of INR 39 million in Q2 FY26
3. Noida facility resulted in EBITDA loss of INR 197 million during the quarter

About Global Health Limited (Medanta)

Founded by Dr. Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon who has been awarded the prestigious Padma Bhushan and the Padma Shri, the third- and fourth-highest civilian awards in India, and the Dr. B.C. Roy Award in recognition of his distinguished contribution to medicine.

Global Health Limited (the “Company”) is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India, with key specialties cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology, according to the report titled “An assessment of the healthcare delivery market in India, September 2022” by CRISIL Limited.

Under the “Medanta” brand, the Company has a network of six hospitals currently in operation (Gurgaon, Indore, Ranchi, Lucknow, Patna and Noida). Spanning an area of 5.6 million sq. ft., its operational hospitals have 3,435 installed beds as on September 30, 2025. It also has four upcoming hospitals in Mumbai, Pitampura - New Delhi, South Delhi and Guwahati. The Company provides healthcare services in over 30 medical specialties and engages over 2,150 + doctors led by highly experienced department heads.

For more information visit www.medanta.org or contact:

Global Health Limited	
Ravi Gothwal ravi.gothwal@medanta.org Tel: 0124 – 4141 414	Bhushan Khandelwal bhushan.khandelwal@medanta.org Tel: 0124 – 4141 414

Safe Harbour Disclaimer

This press release, apart from historical information, contains some “forward-looking statements” including those describing the Company’s strategies, strategic direction, objectives, future prospects, estimates etc. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by these statements. These factors include, but are not limited to general market conditions, macro-economic, movements in currency exchange and interest rates, the ability to attract and retain high quality human resource, competitive pressures, technological developments, governmental and regulatory trends, legislative developments, and other key factors beyond the control of the Company.

These forward looking statements are based on information currently available to us, and we assume no obligation to revise these statements as circumstances change. The Company may alter, modify or otherwise change in any manner the content of Presentation/Press Release, without obligation to notify any person of such revision or changes.